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https://doi.org/10.1016/j.celrep.2020.108181SUMMARYHemopexin (Hx) is a scavenger of labile heme. Herein, we present data defining the role of tumor stroma-
expressed Hx in suppressing cancer progression. Labile heme and Hx levels are inversely correlated in the
plasma of patients with prostate cancer (PCa). Further, low expression of Hx in PCa biopsies characterizes
poorly differentiated tumors and correlates with earlier time to relapse. Significantly, heme promotes tu-
mor growth and metastases in an orthotopic murine model of PCa, with the most aggressive phenotype
detected in mice lacking Hx. Mechanistically, labile heme accumulates in the nucleus and modulates spe-
cific gene expression via interacting with guanine quadruplex (G4) DNA structures to promote PCa growth.
We identify c-MYC as a heme:G4-regulated gene and a major player in heme-driven cancer progression.
Collectively, these results reveal that sequestration of labile heme by Hx may block heme-driven tumor
growth and metastases, suggesting a potential strategy to prevent and/or arrest cancer dissemination.INTRODUCTION
Heme is a high-energy prosthetic group of hemoproteins, whose
functions range from transcription factors (i.e., neuronal PAS
domain protein 2 [NPAS]), gas carriers (i.e., hemoglobin), and cy-
tochromes to redox enzymes (Dutra and Bozza, 2014; Wegiel
et al., 2015). Labile heme traffics between the cytosolic and nu-
clear compartments (Hanna et al., 2016; Yuan et al., 2016;
Soares and Hamza, 2016). The uptake of hemoglobin or labile
heme is provided by myeloid cell receptors CD163 or CD91/
LRP1 by binding hemoglobin:haptoglobin (Hp) or heme:hemo-
pexin (Hx) complexes, respectively (Hvidberg et al., 2005; Kris-
tiansen et al., 2001). Hx has picomolar affinity toward heme;
thus, any changes in its levels lead to abnormalities in heme
clearance. Hx role is critical during hemolysis and heme-associ-Cel
This is an open access article under the CC BY-Nated pathologies, such as sepsis, sickle cell disease, or athero-
sclerosis. However, there are no reports, to our knowledge, on
the role of Hx in cancer. Clinically, colon cancer (in which gastro-
intestinal bleeds are common) or other cancers (i.e., endometri-
osis-associated ovarian cancer) are directly exposed to red
blood cell (RBC) lysis because of bleeding and thus to hemoglo-
bin and labile heme. The relevance of hemolysis to any cancer
type is high because of excessive angiogenesis and/or intra-tu-
moral hemorrhage and metastatic spread.
Elevated labile heme is a characteristic of malaria (Ferreira
et al., 2008), sickle cell disease (Ferreira et al., 2011), and por-
phyrias (Straka et al., 1990). Interestingly, individuals with ma-
laria have higher incidence of cancer (Lehrer, 2010), indicating
a possible role of heme in carcinogenesis. Heme induces hyper-




OPEN ACCESSmucosa-depleted foci in the large intestine (van der Meer-van
Kraaij et al., 2005). Increased intake of red meat and thus high
levels of heme in the intestinal tract may promote colonic inflam-
mation and damage associated with a higher risk of colon cancer
(Takachi et al., 2011). However, the role of labile heme in cancer
and normal biology beyond its oxidant properties remains un-
clear (Glei et al., 2006).
Previous work suggests that the heme porphyrin ring interca-
lates into G-quadruplex (G4) DNA structures, affecting their sta-
bility and function (Poon et al., 2011; Saito et al., 2012a, 2012b;
Sen and Poon, 2011; Shibata et al., 2016; Yamamoto et al.,
2015). G4s are DNA and RNA non-canonical structures held
together by guanine base quartets and stabilized by specific cat-
ions (Kosman and Juskowiak, 2016; Shumayrikh et al., 2015;
Zhang et al., 2016). Moreover, G4 DNA can sequester labile
heme to form DNA:heme complexes, which act as DNAzymes,
exhibiting robust peroxidase and peroxygenase activities (Sen
and Poon, 2011; Travascio et al., 1999). These enzymatic activ-
ities of G4:heme complexes because of their high reactivity of
the iron have been studied in vitro, but no functional studies on
the these complexes have, to our knowledge, been reported
(Gray et al., 2019). G4 DNA motifs accumulate within transcrip-
tionally active euchromatin regions (Hänsel-Hertsch et al.,
2016) and coincide with critical regulatory regions of the
genome, including telomeres and oncogene promoters (i.e.,
c-MYC) (Brooks and Hurley, 2010; Brooks et al., 2010). As
such, these structures are known to have a role in many cellular
processes regulating DNA replication and controlling gene
expression (Biffi et al., 2014a; Eddy et al., 2011; Gray et al.,
2014; Guo and Bartel, 2016; Hänsel-Hertsch et al., 2016;
McLuckie et al., 2013; Murat and Balasubramanian, 2014; Rodri-
guez et al., 2012; Siddiqui-Jain et al., 2002). As an example, the
nuclease hypersensitive element III1 (NHE III1), located up-
stream of the c-MYC promoter, contains G4 DNA motifs that
act as transcription repressors regulating 80% of c-MYC
expression (Ambrus et al., 2005; Siddiqui-Jain et al., 2002).
Therefore, G4s are considered to be ideal targets for anti-tumor
drug development, and several ligands are being developed and
tested for therapeutic approaches (Balasubramanian et al.,
2011; Biffi et al., 2014a; Drygin et al., 2009; Guo and Bartel,
2016; Hänsel-Hertsch et al., 2016; McLuckie et al., 2013; Murat
and Balasubramanian, 2014; Rodriguez et al., 2012). Notably,
binding of small molecules and/or ligands to the G4 structures
can activate an R-loop-dependent DNA damage response,
which will ultimately lead to different cellular consequences
commensurate with the concentration and chemical nature of
the ligands as well as their binding mode and selectivity for spe-
cific G4 motifs (Hampel et al., 2013; Hu et al., 2019; Paul et al.,
2020; Amato et al., 2018).
In this study, we provide direct evidences of Hx and heme
functions in the tumor microenvironment using in vivo prostate
cancer murine models in Hx/ mice as well as a large cohort
of human cancer biopsies and plasma samples. Our findings
demonstrate a previously unknown role and mechanism for
labile heme in cancer growth and metastatic progression via
G4:heme interaction and regulation of key G4-driven oncogenes
thus suggest potential innovative therapeutic targets for cancer
treatment.2 Cell Reports 32, 108181, September 22, 2020RESULTS
Plasma Levels of Heme and Hx in Patients with PCa: Hx
Associates with Clinical Outcome
To investigate whether retention of labile heme in the circulation
and tumor microenvironment could be a marker for cancer pro-
gression, wemeasured the plasma levels of heme and Hx in a set
of 26 patients with prostate cancer (PCa) and 7 healthy volun-
teers. We detected significantly higher levels of labile heme (Fig-
ure 1A) and lower levels of its scavenger Hx (Figure 1B) in the
plasma of patients with cancer (low- or high-grade tumors)
compared with healthy controls. Second, we validated the rele-
vance of these findings in a larger cohort of PCa, including ma-
lignant and benign prostatectomy specimens from 341 patients
(Mulvaney et al., 2016) and analyzed Hx expression in a tissue
microarray (TMA) by immunohistochemistry. The Hx staining in
the stroma was significantly weaker in moderately (Gleason
score [GS] % 7) and poorly differentiated (GS > 7) tumors as
compared with benign tissues (Figures 1C and 1D), similar to
what we observed in the plasma samples (Figure 1B).
Next, we assessed whether Hx in the tumor stroma could be
used as predictive marker for cancer progression. Remarkably,
low Hx levels in the stroma correlated with poor prognosis and
earlier disease relapse based on the rising prostate-specific an-
tigen (PSA) levels (biochemical recurrence [BCR]) (Figure 1E),
whereas no major differences in the Kaplan-Meier progression-
free survival curves based on the levels of Hx in cancer epithelial
cells or stroma from benign tissues was observed (Figures 1F,
S1A, and S1B). Interestingly, high Hx levels (based on the me-
dian H score cutoff) in the benign epithelium correlated with a
better prognosis (Figure S1A).
Because labile heme is derived in large part from hemoglobin,
we evaluated whether hemoglobin and Hx mRNA expression is
altered in metastases of PCa. Interestingly, we found higher
levels of hemoglobin subunit alpha 2 (HBA2) andHx inmetastatic
tumors (Figures S1C and S1D) from the same Geo-profile-sam-
ple set previously used to show upregulation of heme oxygen-
ase-1 (HO-1, encoded by Hmox1) expression in metastatic
PCa (Nemeth et al., 2015).
Heme Increases Metastatic Outgrowth of Cancer
To assess whether changes of labile heme could promote tumor
growth and progression in a mouse model in vivo, we injected
PC3 cells subcutaneously in immuno-compromised animals,
and we treated established tumors with Fe (III) heme (35 mg/
kg, intraperitoneally [i.p.] daily, for 2 weeks) (hemin; referred as
‘‘heme’’ in prior research [Hedblom et al., 2019; Larsen et al.,
2010] and throughout the text here for consistency) daily for
the following 2 weeks. This dose of heme neither affected
body weight nor survival of mice (data not shown). In agreement
with previously published results using the same in vivo model
but less frequent and slightly lower doses of heme (Leonardi
et al., 2019), we did not observe a significant difference in the
overall tumor volume in mice treated with heme compared with
untreated mice (Figure S2A). However, we showed increased
local invasion (Figure 2A) and detected higher numbers of lymph
node (LN) metastases after heme treatment (Figure 2B). Consis-
tently, the significant proliferation of cancerous cells in the tumor
Figure 1. Hx Levels Correlate with a Better Outcome for Patients with PCa
(A and B) Measurements of heme and Hx levels in plasma samples obtained from patients with PCa. Low grade, patients with Gleason scores (GSs) of 6 or 7; high
grade, patients with GSs of 8 or higher; healthy volunteers, donors with unknown cancer diagnoses. Scatter plot represents each measurments and median.
ANOVA, *p < 0.05, **p < 0.01.
(C) Representative staining with an antibody against Hx in benign and cancer (well-differentiated, GSs < 7;moderately differentiated, GS = 7; poorly differentiated,
GS > 7) tissues from 341 patients with PCa using tissue microarrays (TMAs). Scale bar 100 mm.
(D) Relative H score (= Intensity3 Percentage of positive cells) of stromal Hx staining in the 341 patients with PCa and corresponding benign tissues. Number of
cores used for each group is shown. Bar chart represents mean ± SEM. ANOVA, *p < 0.05, ***p < 0.001.
(E and F) Progression-free survival curves based on the BCR are shown in a follow-up for 200months from initial prostatectomy. H scores for Hx in stroma (E) and
in cancer cells (F) were analyzed with themedian value as a cutoff for the survival analysis. Hazard ratio (95%confidence interval [95%CI]) for (E), 3.25 (1.50–7.08),
**p = 0.002. Hazard ratio (95% CI) for (F), 1.13 (0.71–1.79), p = 0.619.
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panied by an upregulation of c-Myc, increased levels of Rb phos-
phorylation, and heme oxygenase-1 (HO-1) expression (Fig-
ure 2D). No changes in the expression levels of total Rb or HO-
2 were detected (Figure 2D). Importantly, the increase of c-
MYC at themRNA levels suggested increased gene transcription
(Figure S2B). We did not observe a difference in Hmox1 mRNA
expression levels in the mouse stroma cells (Figure S2C), sug-
gesting that HO-1 is induced by heme primarily in cancer cells
in the tumor microenvironment (Figure 2D).
To validate our findings in a clinically more relevant model, we
implanted transgenic adenocarcinoma of the mouse prostate
(TRAMP-C1; murine PCa cells) orthotopically into immunocom-
petent C57Bl6 mice (Figures 2E–2M) and treated those mice
bearing established tumors in the prostate with heme. We
observed enlarged tumors and increased numbers of LN metas-
tases in mice treated with heme compared with control mice
(Figure 2E–2H). Ki67 levels in both tumors and LN metastases
were significantly higher in mice treated with heme than they
were in control mice (Figures 2H and 2I). Further, tumors of ani-
mals treated with heme expressed higher levels of c-MYC and
markers of invasion, such as matrix metalloproteinase-2(MMP2) and 9 (MMP9) and urokinase-type plasminogen acti-
vator (uPA) (Figures 2J–2M).
Heme Sequestration by Hx in the Tumor Niche Blocks
Aggressive Cancer Phenotype In Vivo
To assess the role of Hx in heme sequestration and inmodulation
of tumor growth, we used Hx knockout mice (Hx/) in the ortho-
topic prostatemodels described above (Figure 2E).We reasoned
that if heme is not scavengedbyHx in the tumor stromaor plasma
via heme:Hx:CD91 receptor complexes, it should become
directly available for cancer cells via cell membranes and/or
heme transporters. PCa cells possess multiple known heme
transporters, including Abcg2, Flvcr1, and Hrg1, which are all
highly expressed relative to CD91 or Flvcr2 (data not shown).
TRAMP-C1cells implantedorthotopically into theprostatedevel-
oped bigger tumors in Hx/ mice compared with Hx+/+ mice
(Figure 2E). Further, Hx/ mice with established TRAMP-C1 tu-
mors and treated with heme developed significantly larger tu-
mors and more LN metastases compared with untreated mice
(Figures 2E–2I). Of note, increased expression levels of c-MYC
and markers of invasion (MMP9, MMP2, and uPA) in Hx/ tu-
mors were observed upon heme treatment (Figures 2J–2M).Cell Reports 32, 108181, September 22, 2020 3
Figure 2. Role of Heme and Heme-Associated Proteins in Cancer Progression In Vivo
(A–C) PC3 xenografts were established in nu/numice for 2 weeks, and animals were treated with heme (35mg/kg, i.p., daily) for the following 2 weeks. n = 3mice/
group with two tumors/mouse. Representative images and number of Ki67-positive cells infiltrating the local tumor stroma (A) or the LN (B) evaluated as a
percentage of the control (n = 8–12 LNs/group). Scale bar 50 mm. Quantification of Ki67-positive cells is shown in (C). Scatter plot represents mean ± SEM.
ANOVA, **p < 0.01.
(D) Immunoblot analysis of tumor lysates from PC3 xenografts as in (A)–(C).
(E) TRAMP-C1 tumors were established in Hx+/+ and Hx/ mice for 1 week, and animals were treated with heme (35 mg/kg, i.p., daily) for the following 4 weeks.
Tumor size was measured with caliper at the time of sacrifice. n = 8 (Hx+/+, control), n = 15 (Hx+/+ , heme), n = 5 (Hx/, control), n = 8 (Hx/, heme). ANOVA,
*p < 0.05, **p < 0.01.
(F and G) Representative images (F) and number of Ki67-positive cells (G) infiltrating the local tumor stroma evaluated as number of stained cells per field of view
(FOV). Scale bar 50 mm. ANOVA, **p < 0.01, ***p < 0.001.
(H and I) Representative images (H) and number of Ki67-positive cells (I) infiltrating the LNs evaluated as the number of stained cells per FOV. Scale bar 50 mm. Bar
charts represent mean ± SEM. ANOVA, *p < 0.05, ***p < 0.001.
(J–M) qPCR analyses of c-MYC (J), MMP-2 (K), MMP-9 (L), and uPA (M) in TRAMP-C1 tumors established in Hx+/+ and Hx/ mice and treated as described
above. Bar charts represent mean ± SEM. ANOVA, *p < 0.05, **p < 0.01, ***p < 0.001.




Figure 3. Heme Accelerates Tumor Growth
and Accumulates in the Nucleus of Cancer
Cells
(A) Anchorage-independent growth in soft agar of
PC3 cells treated with hemoglobin (10 mM) for
3 weeks. Scatter plot represents mean ± SEM.
n = 3 experiments performed in triplicate. Stu-
dent’s t test, **p < 0.01.
(B) Anchorage-independent growth in soft agar of
PC3 cells treated with heme (1–50 mM) for
3 weeks. Scatter plot represents mean ± SEM.
n = 4–5 experiments performed in triplicate.
ANOVA, **p < 0.01, ***p < 0.001.
(C) Immunoblot analysis of cyclin B1, HO-1, and
HO-2 levels in PC3 cells treated with heme (50 mM)
over a 24-h time course. n = 4–5 independent
experiments.
(D–G) Cell cycle analysis of PC3 cells treated with
heme (50 mM) for 8 h and 24 h. Representative
graphs are shown in (D) and (E), and quantifica-
tions are presented in (F) and (G). Bar charts
represent mean ± SEM. n = 3 independent
experiments performed in duplicate. ANOVA,
*p < 0.05.
(H) Representative images of the nuclear heme
measured by the nuclear heme sensor (ascorbate
peroxidase containing a nuclear localization signal
[APX-NLS]) in PC3 cells treated with heme (50 mM)
for 24 h. Two examples of cells (strongly and
medium positive) with APX-NLS staining are
shown. Scale bar 25 mm. n = 3 independent
experiments.
(I) Detection of heme levels in the subcellular
fractions of PC3 cells at 30 min and 1, 2, 4, and
24 h after addition of exogenous heme. Scatter
plot represents mean ± SEM. n = 3 independent
experiments. ANOVA, ***p < 0.001.
(J) Detection of heme basal levels in the subcellular fractions of BJ fibroblasts (EHZ, ELT, and ELR) as measured by benzidine staining. Scatter plot represents
mean ± SEM. n = 3 independent experiments. ANOVA, *p < 0.05, ***p < 0.001.
(K) Detection of heme basal levels in subcellular nuclear and cytoplasmic fractionations of PNT1A, LNCaP, PC3, DU145, and TRAMP-C1 cells. n = 3 independent
experiments performed in triplicate. Bar charts represent mean ± SEM. Student’s t test, **p < 0.01, ***p < 0.001.
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across multiple tumor types, we tested a similar approach using
a lung cancer model (Figures S2D–S2F). In response to heme
treatment, mice bearing subcutaneously implanted murine
Lewis lung carcinoma (LLC) tumors showed increases in Ki67
staining at the edge of the tumor with invasive behavior (Figures
S2E and S2F). Consistently, LLC cells inoculated intoHx/mice
also displayed an invasive behavior at the edge of the tumors
(Figures S2E and S2F). The increase in c-Myc levels was accom-
panied by both elevated total and phosphorylated Rb in LLC tu-
mors (Figure S2D).
Heme Promotes Growth of Colonies in Soft Agar and
Affects Cell Cycle
Because both hemoglobin and Hx are associated with more
aggressive phenotypes, we evaluated whether heme derived
from hemoglobin could similarly affect the growth of the human
prostatic carcinoma cell line. Hemoglobin promoted colony
growth of PC3 in soft agar in vitro (Figure 3A); similarly, heme
treatment of PC3 cancer cells led to larger and more-numerous
colonies in soft agar in a dose-dependent manner (Figures 3Band S3A). Moreover, addition of heme to cancer cells activated
cell-cycle-related pathways by inducing cyclin B1 and HO-1
expression levels (Figure 3C) and promoting the transition of
PC3 cells through the G1-S and G2-M cell cycle phases (Figures
3D–3G, S3B, and S3C). In the presence of labile heme, fewer
cells accumulated in the G1 phase at 8, 24, and 48 h, whereas
the number of cells in G2/M phases was significantly higher at
24 and 48 h (Figures 3D–3G, S3B, and S3C), suggesting prolifer-
ative advantage in response to heme.
Labile Heme Accumulates in the Nucleus of Cancer
Cells
Because we observed a strong induction of cell-cycle regulatory
molecules by heme, we measured the intracellular heme levels.
Using a nuclear-targeted heme sensor (Yuan et al., 2016) (Fig-
ure 3H) and colorimetric measurements (Figure 3I), we demon-
strated the uptake and accumulation of heme in the nucleus
upon treatment with exogenous heme in PC3 cells or fibroblasts
(Figures 3I, S3D, and S3E). Nuclear heme levels were increased
upon the addition of exogenous heme, reaching a plateau levels
at 2–4 h after treatment of PC3 cells and returning to the baselineCell Reports 32, 108181, September 22, 2020 5
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ures 3I and 3C). The successful fractionations and HO-1 induc-
tion in the samples were confirmed (Figures S4A–S4D). We
then assessed the basal levels of labile heme in the nuclear
and cytoplasmic compartments of several normal (BE [human
bronchial epithelial cells] and PNT1A [normal human prostate
epithelium]) and cancer cell lines: PCa (LNCaP, DU145, PC3,
and TRAMP-C1), lung cancer (A549 and LLC), as well as in the
transformed BJ fibroblasts (Figures 3J–3K and S3E). Interest-
ingly, basal labile heme levels were markedly higher in the nu-
clear fractions of cancer cell lines compared with normal epithe-
lial cells (Figures 3K and S3E). Remarkably, the basal level of
heme accumulation in the nucleus of fibroblasts was propor-
tional to the degree of cellular transformation determined by
the number of oncogenes introduced into the BJ fibroblasts
(EHZ [hTERT], ELT [hTERT, large T antigen], and ELR [hTERT,
large and small T antigen, HRas]) (Boehm et al., 2005) (Figure 3J).
Moreover, the accumulation of nuclear labile heme levels was
more pronounced in metastatic cancer cells (Figure 3K), indi-
cating a possible correlation between nuclear labile heme and
aggressiveness.
Heme Modulates a Subset of Genes Related to Cell
Cycle and Cancer Progression
Because heme accumulates in the nuclear compartment in can-
cer cell lines, we asked whether heme could affect gene expres-
sion. We performed RNA sequencing (RNA-seq) analysis on PC3
cells treated with heme. To analyze the effect of heme on gene
expression, we decided to collect cells at early time points (2
and 4 h upon treatment with heme), when the expression of
HO-1 protein is still not detectable and thus the levels of heme
are higher (Figures 3C and 3I). As expected, the top genes
induced or repressed by heme after 4 h treatment were Hmox1
and 50-aminolevulinate synthase 1 (ALAS1), which are both key
enzymes involved in the degradation or de novo synthesis of
heme, respectively (Table S1). Hmox1 mRNA was upregulated
as early as 2 h after treatment and remained elevated at 4 h (Fig-
ure 4A); however, the protein was not detectable before 4 to 6 h
after heme treatment (Figure 3C). In our RNA-seq analysis,
ALAS1 expression was initially upregulated at 2 h (6-fold) and
then suppressed by heme at 4 h as a negative feedback loop
(Furuyama et al., 2007) (Tables S1 and S2). Consistent with our
other findings (Figures 3C–3G), heme treatment significantly
perturbed genes involved in cell-cycle progression leading to
downregulation of CCNE1, CCNA2, CCNE2, E2F2, and TGFB3
or upregulation of others, i.e., CCNA1, MYC, and CDKN1A at
2 h (Figure 4A). Similarly, genes associated with cell-cycle
checkpoint, estrogen-mediated S-phase entry and cancer me-
tastases (WNT, transforming growth factor beta [TGF-b], and
MAPK/Erk1/2 pathways) were also altered by the addition of
heme as assessed by pathway analysis (Figures 4B–4D). Impor-
tantly, gene enrichment analysis showed early induction of Ap-1
pathway genes, such as c-MYC, FOSB, MMP9, or ERG1 (Fig-
ures 4E and 4F) and reduction of genes associated with rRNA
processing (UTP15, DKC1, and UTP6). The top genes altered
by heme are included in Figures 4E and 4F. The pattern of
gene enrichment in response to heme was reversed after 4 h
(Figure 4F).6 Cell Reports 32, 108181, September 22, 2020By performing real-time PCR (Figures 4G–4P), we confirmed
that Hmox1 was strongly induced by heme in PC3 cells at 2
and 4 h (Figure 4G), and it was highly elevated in the tumors im-
planted into Hx+/+ or Hx/ mice and treated with heme (Fig-
ure 4I). ALAS1 mRNA was induced by heme in PC3 cells after
2 h, but its expression returned to the baseline levels at 4 h af-
ter heme treatment (Figure 4H). There was no significant effect
of heme on ALAS1 mRNA in tumors in vivo (Figure 4M). A
similar mRNA pattern of gene-expression change to Hmox1
was detected for the zinc finger 469 (ZNF469) gene (Figures
4I and 4N). Furthermore, heme treatment led to higher and tran-
sient expression of genes controlling autophagy and metasta-
ses, AMIGO2 (amphoterin-induced gene and open reading
frame 2), and ULK1 (Unc-51 like autophagy activating kinase
1) in PC3 cells after 2 h (Figures 4J and 4K). Those genes
were also elevated in tumors isolated from mice treated with
heme on the wild-type and Hx/ background (Figures 4O
and 4P).
Heme Induces c-MYC-Dependent uPA Expression
To assess the contribution of one of the top heme-regulated
genes, c-MYC, in heme-mediated cellular effects, we stably
transduced PC3 cells with short hairpin (sh) RNAs targeting
c-MYC and achieved50%knockdown of themRNA (Figure 5A)
and protein (Figure 5B) suppressing heme-induced c-MYC
expression without affecting their survival. Although induction
of both MMP2 and uPA was observed in control non-targeting
shRNA PC3 cell upon heme treatment, only uPA displayed a c-
MYC-dependent expression (Figures 5C and 5D). Indeed,
knockdown of c-MYC blocked basal and heme-induced uPA
levels (Figure 5D). Importantly, shRNA-mediated c-MYC down-
regulation was able to limit the heme-induced colony growth
(Figure 5E).
More than 75% of c-MYC transcriptional activity is controlled
byG4 sequences embedded in the gene promoter (Siddiqui-Jain
et al., 2002). Interestingly, we found that the effect of heme on
colony growth was blocked in cells concurrently treated with
the well-established c-MYC G4 stabilizing molecule, GQC-05
(Figure 5F), suggesting the requirements of c-MYC expression
for heme-induced cancer growth. Notably, GQC-05 completely
suppressed c-MYC expression (Figure 5G), in striking contrast
to heme (Figure 5G), but at the dose of 10 mM used in this study
did not affect cell survival/growth as measured by crystal violet
staining (Figure 5H). Consistently, GQC-05 strongly inhibited
c-myc protein expression in a dose-dependent manner (Brown
et al., 2011), whereas no changes in vascular endothelial growth
factor (VEGF) levels were observed (Figure 5G). On the contrary,
heme treatment was associated with increased c-myc protein
expression (Figure 5G).
These findings indicate that heme promotes uPA expression in
a c-MYC-dependent manner and demonstrate a heme-medi-
ated control of c-MYC expression, potentially by altering
c-MYC G4 structures stability (Figure 5G).
Heme:G4 Complexes Regulate Cancer Growth
Heme is able to stabilize the G4-containing sequence (also
known as Pu27) within the c-MYC promoter (Siddiqui-Jain
et al., 2002) (Figures 5I and 5J). We detected little changes in
Figure 4. Heme Induces Selective Genes Controlling Metastases and Cell Cycle Progression
(A–F) Analysis of RNA-seq data from PC3 cells treated with heme (50 mM) for 2 h or 4 h and control cells. Heatmap is shown in (A). n = 2 per group. (B)–(D) Pathway
analysis of the gene expression profiles as in (A). (E and F) Gene set enrichment analysis based on the functional annotation of the differentially expressed genes
identified two key pathways: AP-1 and rRNA modification pathways in response to heme. The genes enriched within the pathways are labeled in red if they
contain G4 in their regulatory elements.
(G–K) qPCR analysis of Hmox1 (HO-1) (G), ALAS1 (H), ZNF469 (I), AMIGO2 (J), and ULK1 (K) in PC3 cells treated with heme (50 mM) for 2 h or 4 h. Bar charts
represent mean ± SEM. ANOVA, *p < 0.05, **p < 0.01, ***p < 0.001.
(L–P) qPCR analysis of Hmox1 (HO-1) (L), ALAS1 (M), ZNF469 (N), AMIGO2 (O), and ULK1 (P) in TRAMP-C1 tumors established in Hx+/+ and Hx/ mice and
treated with heme as above. Bar charts represent mean ± SEM. ANOVA, *p < 0.05, **p < 0.01.




Figure 5. Heme Activates c-MYC Expression in Part via Binding to DNA G4 Structure in Its Promoter
(A and B) qPCR (A) andwestern blot (B) analysis of c-MYC in PC3-sh-control and PC3-sh-c-myc cells treatedwith heme (50 mM) for 2 h or 4 h. Bar charts represent
mean ± SEM. ANOVA, *p < 0.05, ***p < 0.001.
(C and D) qPCR analysis ofMMP2 (C) and uPA (D) in PC3-sh-control and PC3-sh-c-myc cells treatedwith heme (50 mM) for 2 h or 4 h. Bar charts represent mean ±
SEM. ANOVA: *p < 0.05, **p < 0.01, ***p < 0.001.
(E) Anchorage-independent growth in soft agar of PC3-sh-control and PC3-sh-c-myc treated with heme (50 mM) for 3 weeks. Scatter plot represents mean ±
SEM. n = 3 independent experiments. ANOVA, *p < 0.05. n.s., not significant.
(F) Anchorage-independent growth in soft agar of PC3 cells cultured in the presence or absence of GQC-05 (10 mM) or vehicle (DMSO) with or without heme
(50 mM) for 3 weeks. Bar chart represents mean ± SEM. n = 3 experiments performed in triplicate. ANOVA, ***p < 0.001.
(G) Western blot analysis of c-myc, VEGF, and lamin A/C in cell lysates from PC3 cells treated with heme (50 mM) or GQC-05 (10 mM) for 0.5–8 h. A representative
blot of three independent experiments is shown.
(H) Crystal violet staining of PC3 cells treated for 48 h with GQC-05 (10 mM). Bar chart represents mean ± SEM. n = 3 independent experiments.
(I) CD spectra with 1:1 heme:Pu27 ratio demonstrating molecular ellipticity at 262 nm. The peak is maintained upon addition of heme, indicating a parallel G4
structure.
(J) Melting temperature of the heme:Pu27 complexes evaluated at 262 nm by CD. Melting temperature for pu27 oligonucleotide was 72.36C, for Pu27:heme, 1:1
was 78.27C, and for Pu27:heme, 1:2 was 84.15C.
(K) EMSAwas performed using the wild-type G4-Pu27 (p27) or the mutated G4-Pu27 (mp27) sequence found in the c-MYC promoter region in the presence of an
antibody against G4 (BG4). Results are representative of three experiments.
(legend continued on next page)






OPEN ACCESSthe circular dichroism (CD) spectrum upon addition of heme,
supporting the idea that G4 structures are likely being main-
tained or slightly distorted, as confirmed by a measurement of
the melting temperature upon the addition of heme to G4 DNA
sequence in vitro (Figure 5J).
To address the heme:G4 interaction, we used an anti-G4 anti-
body (the BG4 immunoglobulin G [IgG]) that recognizes G4
structures (Biffi et al., 2014b) and IgG control. We observed spe-
cific binding between the BG4 antibody and the Pu27 c-MYC
promoter sequence forming G4 structures (Figure 5K), whereas
no binding occurred between Pu27 c-MYC and IgG control (Fig-
ure 5K). Such complexes were lost when a mutated Pu27 (pu27-
M) sequence, which is unable to form G4 in vitro, was used (Fig-
ure 5K). These results led us to test whether heme could complex
directly with G4 structures (Figure 5L). A strong interaction be-
tween heme and G4 was confirmed with the Pu27 c-MYC pro-
moter sequence as a model (Figure 5L). Chromatin immunopre-
cipitation (ChIP) with anti-BG4 antibody in the PC3 cells showed
suppression of G4 structures in the c-MYC promoter 0.5–2 h af-
ter heme treatment and enrichment to baseline levels at 4 h (Fig-
ure 5M). The G-quadruplex recognition, stabilization, and un-
winding at Pu27 is controlled by four major proteins: (1)
nucleolin (involved in the formation and stabilization of G4 in
c-MYC promoter [González et al., 2009]), (2) non-metastatic
23-H2 (NM23-H2, a transactivator of c-MYC) (Berberich and
Postel, 1995), (3) cellular nucleic-acid-binding protein (CNBP,
an activator of parallel G4 structure) (Borgognone et al., 2010;
Chen et al., 2013; Michelotti et al., 1995), and (4) heterogenous
nuclear ribonucleoprotein K (hnRNPK, an activator of c-MYC
expression by binding to single-stranded DNA) (Tomonaga and
Levens, 1995). Therefore, we examined by ChIP whether recruit-
ment of these four factors to the G4-rich region of c-MYC pro-
moter was impaired in PC3 cells treated with heme. We
confirmed the effective immunoprecipitation with the specific
antibodies by western blot (Figures S5A and 5B). We detected
CNBP and NM23-H2 in immunoprecipitates from control or
heme-treated cells with anti-CNBP or anti-NM23-H2 antibodies,
respectively (Figure S5A). We also confirmed the same efficiency
of pull-down with antibodies against hnRNPK and nucleolin in
the ChIP samples (Figure S5B). We found that the interaction
of all four proteins with the c-MYC promoter was hampered at
2 h after heme treatment (Figures 5N, S5A, and S5B) with the
most significant decreased enrichment of NM23-H2. Interest-
ingly, the enrichment of CNBP at Pu27 was only slightly but
not significantly decreased in cells treated with heme compared
with untreated cells (Figure 5N).
Immunofluorescence staining of heme-treated cells using the
BG4 antibody revealed increased G4 content in both the nu-
cleus and cytoplasm of PC3 cells at 24 h after treatment with
heme (Figure 5O), which aligns with our findings of dynamic(L) EMSA was performed using p27 and mp27 G4 sequences incubated for 20 m
independent experiments.
(M) ChIP analysis with anti-BG4 antibody in PC3 cells treated with heme (50 mM)
Bar chart represents mean ± SEM. ANOVA, **p < 0.01, ***p < 0.001.
(N) ChIP analyses with anti-nucleolin, anti-NM23-H2, anti-CNBP, and anti-hnRNP
experiments performed in duplicates. Bar chart represents mean ± SEM. ANOVA
(O) Immunofluorescence staining for BG4 in PC3 cells treated with 50 mM hemechanges in G4 content in response to heme. Because the
pattern of G4 enrichment in the c-MYC promoter corresponded
to the expression pattern of c-MYC observed by RNA-seq (low
G4 at 2 h corresponds to high c-MYC expression and baseline
G4 at 4 h to baseline level of c-MYC levels in heme-treated
cells), we sought to determine whether the genes responsive
to heme treatment detected by RNA-seq exhibited G4 regions
in their promoter. Not surprisingly, as many as 60% of the top
heme-regulated genes were enriched in G4 sequences (Fig-
ure 4E; Table S3).
Presence of G4 Structure Correlates Inversely with
Patient Outcome
To assess the clinical significance of G4, we used the TMA of 341
patients with PCa as above (Figure 1) and analyzed nuclear stain-
ing of G4 in epithelial and stroma cells (Figures 6A and 6B).
Advanced PCa biopsies were associated with lowG4 levels (Fig-
ure 6C). Interestingly, low G4 levels correlated with poor prog-
nosis and earlier relapse similarly to Hx (Figure 6D). Strikingly,
three patients with BG4 score <1 displayed very poor prognosis
(Figure 6E). No association with G4 levels was observed for the
cancer stroma component and the stroma or epithelial benign
counterparts (Figures S6A–S6C).
DISCUSSION
In this study, we addressed the question of whether high levels of
labile heme could have a role in cancer progression and how al-
terations of its scavenger Hx might contribute to the aggressive-
ness of the tumor behavior (Figure 6F). The role of heme, beyond
the function of heme present in the cores of proteins, either as
co-factors or regulatory element (i.e., in hemoproteins), is poorly
understood. Heme is part of several nuclear transcription fac-
tors, including Rev-Erba, NPAS2, Bach1, and Drosha (Burris,
2008; Carter et al., 2016; Dioum et al., 2002; Faller et al., 2007;
Yin et al., 2007). Only recently, the identification of multiple
heme transporters and the use of the heme sensors in the nu-
cleus (Hanna et al., 2016; Yuan et al., 2016) have allowed moni-
toring of the trafficking of heme to the nucleus. In this study, we
showed that heme accumulates in the nucleus of cancer cells
and controls expression of key target genes, such as c-MYC,
containing G4 structures in the promoters. Although previous
work suggested that porphyrins interact with G4s and can affect
G4 stability and function (Saito et al., 2012b), the in vivo rele-
vance has never, to our knowledge, been investigated.
Repeated exposures of normal or cancer cells to heme may
occur during hemolysis or cell death as well as upon administra-
tion of heme-arginate, a compound used to treat porphyrias.
Severe hemolysis and premature death in mice lacking the
peroxiredoxin-1 (Prdx1) gene correlate with higher incidence ofin with 50 mM heme before loading in the presence of the BG4 antibody. n = 3
for 0.5, 1, 2, and 4 h. n = 3–4 independent experiments performed in duplicate.
K antibodies in PC3 cells treated with heme (50 mM) for 2 h. n = 2 independent
, **p < 0.01, ***p < 0.001.
for 24 h. Scale bar 20 mm. n = 3 independent experiments.
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Figure 6. BG4 Levels Correlate with Cancer Progression and Progression-free Survival of Patients with Prostate Cancer
(A and B) Representative staining with an antibody against G4 in benign and cancer (well-differentiated, GS < 7; moderately differentiated GS = 7; or poorly
differentiated, GS > 7) tissues from 341 patients with PCa as in Figure 1C. Scale bars 100 mm (A) and 50 mm (B).
(C) Relative H score (= Intensity 3 Percentage of positive cells) of BG4 staining as in Figure 1C. *p < 0.05, ***p < 0.001.
(D and E) Progression-free survival curves based on the BCR are shown in a follow-up for 200 months from initial prostatectomy. Bar chart represents mean ±
SEM. H score for BG4 in cancer cells (D) was analyzed with themedian value as a cutoff for the survival analysis. Hazard ratio (95%CI) for (D), 2.86 (1.38–5.91), p =
0.006. Hazard ratio (95% CI) for (E), 18.84 (5.11–69.39), p = 0.0001. Note: Three patients with negative H score for BG4 were compared with remaining patients
with H score > 1 in (E) to emphasize the role of BG4 in cancer progression.
(F) Scheme illustrating the role of heme and heme-associated proteins in cancer progression. Hemoglobin and heme can be scavenged by Hp or Hx and taken up
by macrophages via binding to CD169 or CD91, respectively. If Hx is not present, heme accumulates in the nucleus of cancer cells and binds to G4 DNA in the
regulatory regions of specific genes to facilitate their expression and progression of cancer.
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OPEN ACCESSmalignancies, such as sarcomas, lymphomas, and carcinomas
(Neumann et al., 2003). Based on our findings, this phenotype
could be ascribed to the heme-induced cancer cell colony
growth and formation ofmetastases in vivo. Interestingly, several
cases of hemolytic uremic syndrome have been described in
advanced PCa patients (Mungall and Mathieson, 2002; Ramos
et al., 2013). We established a strong predictive value of Hx
levels in the stroma of a cohort of 341 patients with PCa and pri-
mary tumors. With plasma from a smaller cohort of patients (n =
26), we discovered an inverse correlation between heme and Hx
levels. Remarkably, higher Hx levels in the stroma, with presum-
ably lower labile heme levels in the tumor, are associated with a
better survival of patients with PCa. A larger cohort of plasma10 Cell Reports 32, 108181, September 22, 2020and urine samples should be tested to assess the role of heme
as a PCa biomarker in the future.We propose that Hx binds labile
hemewith strong affinity allowing its uptake by LPR1/CD91-pos-
itive cells. LPR1/CD91 is expressed at low levels in the stroma of
PCa according to the Human Atlas. Presence of Hx/CD91 in
healthy tissues might be a mechanism that prevents entering
of heme into pre-malignant or cancer cells and promoting their
growth. Interestingly, we found that mRNA levels of Hmox1,
Hx, and HBA2 are highly expressed in metastatic samples of
PCa. The increase in HBA2 could be associated with increase
load of labile heme coming from erythrocytes as well as dying
cancer cells or healthy cells (inflammatory cells) at the tumor
niche. However, we have no direct evidence for the elevated
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OPEN ACCESSheme levels in themetastatic niche, and the levels of HBA2 or Hx
mRNA obtained from Geo Profiles using metastatic samples do
not directly suggest how much free versus protein-bound heme
is present in the niche. Importantly, the biochemical responses
to heme are different from that of heme:Hx complexes and range
from activation of cell growth to apoptosis (Eskew et al., 1999)
but are poorly understood. Prior work indicated that decreased
Hx levels in patients with acute respiratory distress syndrome
(ARDS) or burns and in premature infants may lead to insufficient
clearance of heme and, therefore, administration of Hx may
benefit those patients (Lin et al., 2015).
Metastatic phenotype of tumors exposed to labile heme in the
absence of Hx indicates the essential role of this heme scav-
enger protein in tumor progression. We demonstrated an
increased anchorage-independent growth of cancer cells in
response to heme that correlates with changes in expression
of cell cycle regulators and metastatic genes, such as c-MYC
and metalloproteinases. Several other studies have reported
the importance of MMPs in PCa cell proliferation, invasion, and
metastasis (Quigley et al., 2018; Wegiel et al., 2008) (Wyganow-
ska-Swiątkowska et al., 2019). Of note, we found that heme-
induced c-MYC levels control the expression of uPA, similar to
hypoxia-induced uPA expression (Hou et al., 2007). Because
of its role in the process of extracellular matrix degradation,
uPA is a poor prognostic marker for PCa, and its expression
levels have been associated with distant metastasis and tumor
progression (Duffy, 2002; Nassir, 2020; Shariat et al., 2007). Pre-
vious studies, applying higher doses of heme (70 mM versus the
50 mM dose used in our study) and opposite of pharmacological
kinetics (preconditioning with heme before injection of tumor
cells and not after the tumor is established, as described herein),
reported suppression of PCa cell migration/invasion, MMP9, and
uPA expression upon heme treatment (Gueron et al., 2009; Ja-
worski et al., 2017), in contrast to our results. However, the
reason for that apparent discrepancy is 2-fold. First, the higher
doses of heme may be toxic to cancer cells, whereas the lower
dose may be permissive for invasive growth; second, condition-
ing the mice before the tumor is established and not after, eval-
uates the effect of heme on the immune cell phenotype rather
than in cancer progression.
c-MYC is a potent oncogene aberrantly expressed in approx-
imately 80% of human malignancies (Dejure and Eilers, 2017). In
PCa, c-MYC drives tumor proliferation and the expression of
androgen receptor (AR) gene splice variants, and its levels are
associated with biochemical recurrence after radical prostatec-
tomy (Cui et al., 2020) (Bai et al., 2019; Hawksworth et al., 2010).
However, knockdown of c-MYC in fibroblasts was associated
with reduced levels of c-MYC in the prostate tumor stroma and
led to increased PCa cell invasion (Valencia et al., 2014).
Although these findings may indicate that c-myc could be a tu-
mor suppressor in the cancer stroma, our data clearly show
that heme-induced c-MYC promotes tumor growth. c-MYC
expression is tightly controlled by the presence of G4 within
the promoter (Siddiqui-Jain et al., 2002). The cationic porphyrin,
TMPyP4 can bind to the G4 within c-MYC gene promoter
thereby repressing its transcription (Siddiqui-Jain et al., 2002).
Unlike TMPyP4, TMPyP2 binds less efficiently to the G4 within
the c-MYC promoter. Although TMPyP4 and labile heme sharethe same porphyrin ring structure and cationic center capable
of binding G4 structures, our studies show that, in contrast to
TMPyP4-mediated repression of transcription (Siddiqui-Jain
et al., 2002), heme promotes c-MYC expression. Recent data
show that the G4-stabilizing molecule GQC-05 efficiently in-
creases the CD spectra peak at 262 nm, resulting in a decreased
expression of c-MYC (Brown et al., 2011). We show that GQC-05
blocks heme-mediated colony growth, suggesting that heme
may drive cancer colony formation specifically through c-MYC
promoter engagement and that both molecules may compete
with each other for binding to the G4 structures. We demon-
strated that heme blunts the interaction between c-MYC pro-
moter and G4-interacting proteins nucleolin, NM23-H2, and
hnRNPK at the time when c-MYC mRNA expression peaks.
The early and transient destabilization and unwinding of G4 com-
plexes upon heme treatment (0.5–2 h) is associated with
impaired binding of NM23-H2:G4 and a decreased interaction
of hnRNPK and nucleolin with the pu27 promoter element at 2
h. The presence of CNBP was only slightly, but not significantly,
reduced at the c-MYC promoter in response to heme. CNBP
might contribute to stabilization of parallel G4 structure and
enhanced c-MYC transcription (Borgognone et al., 2010; Chen
et al., 2013). It was shown that CNBP promotes a transient
reduction of c-MYC expression, which is later reversed by inter-
action by CNBP with NM23-H2 (Chen et al., 2013). However,
CNBP was also reported to bind and stabilize the G4 in the pro-
moter of hnRNPK, resulting in suppression of transcription (Qiu
et al., 2014; Qiu et al., 2015). In contrast, CNBP promotes K-
ras expression by unwinding the G4 structure (David et al.,
2019). The dynamic changes in c-MYC promoter occupancy
by those proteins and thus alterations of heme:G4 structures
are likely responsible for the transient but robust induction of
c-MYC expression in response to heme.
Sixty percent of the heme-targeted genes display G4-rich pro-
moters supporting the hypothesis of heme direct binding to
those structures. Our data show that key genes driving cell cycle
(growth factor signaling, cyclins and cell cycle regulators of
S-phase), epithelial to mesenchymal transition (EMT; TGF-b
and Wnt pathways), and inflammation are transiently upregu-
lated by heme before HO-1 protein induction, and many of
them have been previously associated with increased invasive-
ness andmetastases. Most G4-driven geneswithin the identified
AP-1 and rRNA processing pathways return to the baseline 4 h
after heme treatment, which might be due to accelerated
entrance of PC3 cells into the S phase in the presence of
heme. The highly dynamic changes in gene expression are likely
due to a direct interaction of hemewith DNA and transient desta-
bilization of G4 structure in the promoters. In contrast to previous
studies (Biffi et al., 2014b), but in accordancewith the hypothesis
that decreased G4 formation enables gene expression to be
turned on, we demonstrated lower levels of G4 in the nucleus
of patients with poor survival and advanced disease. A compre-
hensive analysis of disease progression was missing in the prior
work. Interestingly, unlike Hx expression, the intenstity of G4
structure staining in the stroma was not correlated with a clinical
outcome. Likely, the heme:G4 quadruplex formation in healthy
cells occurs at low frequency, given the limited ability of healthy
cells to accumulate nuclear heme. By contrast, we showed thatCell Reports 32, 108181, September 22, 2020 11
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OPEN ACCESScancer cells can tolerate accumulation of labile heme in the nu-
cleus, which may explain the modulatory effect on G4 in the can-
cer compartment rather than in the stroma.
In summary, we uncovered the functional role of nuclear labile
heme accumulation as a driver of metastasis via interaction with
G4 structures embedded in the promoter regions of critical
genes such as c-MYC. We described the antitumor function of
Hx and connected scavenging of heme to patient outcome.
Numerous implications that arise from this study include (1) the
potential use of heme levels as a biomarker for patients with
PCa, (2) the reclassification of heme (i.e., red meat or treatment
with heme arginate) as a DNA intercalating agent able to turn on
oncogene expression andmetastatic gene expression profile via
interaction with G4, and (3) the use of Hx and BG4 as clinical bio-
markers associated with cancer dissemination in prostate
malignancies.STAR+METHODS
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naparte, D., Cavalcante, M.M., Chora, A., Ferreira, A., et al. (2010). A central
role for free heme in the pathogenesis of severe sepsis. Sci. Transl. Med. 2,
51ra71.
Lehrer, S. (2010). Association between malaria incidence and all cancer mor-
tality in fifty U.S. States and the District of Columbia. Anticancer Res. 30, 1371–
1373.
Leonardi, D.B., Anselmino, N., Brandani, J.N., Jaworski, F.M., Páez, A.V., Ma-
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Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Dr. Bar-
baraWegiel (Department of Surgery, Beth Israel DeaconessMedical Center, HarvardMedical School, bwegiel@bidmc.harvard.edu).
Materials Availability
This study did not generate any unique reagents.
Data and Code Availability
RNaseq data generated in this study were deposited on Gene Expression Omnibus under the accession number: GSE139091 (a pri-
vate access token is ubmlmigqzlkrdiv, https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE139091).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell lines
Prostate cancer PC3 cells were a gift from Dr. Steven Balk (BIDMC, Boston, MA) and were maintained in RPMI medium (GIBCO, Life
Technologies) supplemented with 10% Fetal Bovine Serum (Atlanta Biologicals). TRAMP-C1 cells were purchased from ATCC and
maintained in DMEM supplemented with 10% Fetal Bovine Serum (Atlanta Biologicals). PC3 Control shRNA or PC3 shRNA c-myc
(Addgene), LNCaP, A549 and PNT1A were previously described (Wegiel et al., 2013). BJ fibroblasts transformed with oncogenes
(ELR, ELT, EHZ) were kindly provided by Dr. Weinberg (MIT, Cambridge, MA) (Boehm et al., 2005) and were cultured in DMEM
high glucose supplemented with 10% FBS. Human bronchial epithelial cells (NHBE) were from Lonza and were maintained in Bron-
chial Epithelial Cell Growth Medium with Supplements as specified by manufacturer’s protocol (Lonza). Cells were maintained in a
37C humidified incubator with 5% CO2 and 21% O2.
Patients samples
Tissues from radical prostatectomies of 341 prostate cancer patients, operated between 1998 and 2006 at SkåneUniversity Hospital,
Malmö, Sweden was used to construct a tissue microarray (TMA) as previously described in (Tassidis et al., 2013). Clinical follow-up
data of minimum 10 years and pathological staging was available for most of the patients and the clinical characteristics have been
previously described in Mulvaney et al. (2016). Plasma samples were from patients undergoing a PSA test at the Malmö University
Hospital between 2004 and 2010 (ethical permit number 2016/1030). The patients were followed up for a minimum of 8 years. All
patients included in this study received a prostate cancer diagnosis after the PSA test, based on positive biopsies. Patients who
received a diagnosis of Gleason score 6 or 7 were defined as ‘‘low grade’’ (n = 16, mean age 72.7) and those with a diagnosis of
Gleason score 8 or higher were defined as ‘‘high grade’’ (n = 10, mean age 70.8). Healthy donors were men with no known cancer
diagnosis (n = 7, mean age 57,1) who volunteered to donate blood at the Malmö University Hospital (ethical permit 2019/02234). The
blood was collected in EDTA tubes and centrifuged for 10minutes at 2000 x g. Plasma was extracted, aliquoted and stored at80C
until further use.
Animal models
Nude nu/numice and C57Bl6 mice were from Jackson Laboratories. Hx/mice were from Tolosano et al. 1999, (2002). For prostate
studies onlymalemicewere used. All animals were kept in ventilated cages (up to fivemice per cage) in a 12-hour light-dark cycle and
were provided water and food ad libitum at all times. The procedures were approved by the Institutional Animal Care and Use Com-
mittees at Beth Israel Deaconess Medical Center.
METHOD DETAILS
Reagents
Fe (III) heme (hemin; referred as ‘heme’ throughout the text) (Sigma-Aldrich) was prepared by dissolving powder in 0.1 N NaOH and
then titrated with 0.1 N HCl to biological pH 7.4, followed by adjustment to the final concentration (10 mM) with saline. Heme stocke3 Cell Reports 32, 108181, September 22, 2020
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the dark at various concentration of 1-50 mM. GQC-05 (Dr. Hurley’s laboratory) was previously described (Brooks and Hurley, 2009;
Brown et al., 2011) and used at 10 mM concentration for treatment in vitro.
Soft agar colony assay
1x104 PC3 cells were suspended in 0.35%biotechnology grade agarose (Amresco) in RPMI supplemented with 10%FBS and plated
before solidifying on a solid 0.5% agarose with RPMI medium supplemented with 10% FBS. Medium was replaced every third day.
Colonies were maintained for 2-3 weeks in a humidified incubator at 37C, followed by staining with methylene blue (Sigma-Aldrich)
and counting individually.
Cell cycle analysis
For cell cycle analysis, cells were serum starved for 48 h and then treated with 50 mMheme for additional 8-48 h. Cells were harvested
and washed in PBS and then fixed in 70% cold ethanol while vortexing. Cells were fixed for at least 30 min at 4C. After fixation, cells
were washed twice in PBS and resuspended in PBSwith RNase (100 mg /ml). Cells were stained with propidium iodide (50 mg/ml) and
analyzed by flow cytometry.
Tumor models
Nude nu/nu mice (Jackson Laboratories, Stock No: 002019) were injected subcutaneously with 5x106 PC3 prostate cancer cells in
each of two flanks per animal. Once tumors were established, mice were injected with heme (35 mg/kg, i.p.) once daily for an addi-
tional two weeks. Tumor sizes were monitored by caliper. LLC tumors were established in C57Bl6/J mice (Jackson Laboratories,
Stock No: 000664) by injecting of 0.5x106 Lewis lung carcinoma cells subcutaneously. Tumors were established in 10-14 days
and mice were treated with heme (35 mg/kg, i.p.) once daily for an additional week. TRAMP-C1 tumors were established by injecting
of 2x106 cells in the prostate of the animals. Tumors were established for 1 week and mice were treated with heme (35 mg/kg, i.p.)
once daily for 4 additional weeks. Tumors were isolated and their sizes were measured by caliper.
BG4 antibody generation
BG4 antibody encoding plasmid (Biffi et al., 2013) was a kind gift of Dr. Balasubramanian Lab (Cambridge University, UK). The single
chain antibody was modified at the Creative Biolabs to generate a human IgG encoding plasmid and transfected into HEK293 cells,
after which the product was purified by HiTrap rProteinG FF and filtered by 0.2 mm. The antibody was aliquoted and frozen at20C
or 80C until use.
IHC and immunostaining
For IHC on TMA, deparaffinized 4-mm sections from the TMA blocks were subjected to antigen retrieval using a PT-Link module
(Dako, Glostrup, Denmark) at 95–99C for 20 min in citric acid buffer (0.01 M, pH 6.0). Immunostaining for BG4 (1:300, Millipore),
HO-1 (1:400, Stressgen) and hemopexin (1:500, Abcam) was performed using EnVision Flex high-pH reagent (Dako) in an Autostainer
Plus system according tomanufacturer’s protocol. In order to distinguish benign from tumor areas, consecutive sections of the TMAs
were also stained for p63 (M7001, 1:50 DAKO) and AMACR (alpha-methyl acyl-CoA racemase; M3616, 1:100 DAKO) respectively.
Gleason score was assigned to each TMA core by a senior National Board certified pathologist with help of hematoxylin & eosin (H&E)
stained tissue sections. The slides were digitized on an Aperio Scanscope scanner and visualized on the Aperio ImageScope soft-
ware (Leica Biosystems, Wetzlar, Germany). Immunostained sections were scored considering the intensity of the staining and also
the percentage of stained cells. Samples were given an intensity score between 0 and 3 (0 = negative, 1 = low, 2 =moderate, 3 = high)
and a positivity score based on the percentage of stained cells (< 10% = 1, 11%–75% = 2, > 75% = 3). These two scores (intensity
score and fraction of positively stained cells) were then multiplied to give a final expression score (H-score, 0-9). Two benign and two
cancer cores from each patient were available and results are based on the average value for the two cores. The total number of cores
analyzed is reported in Table S4.
Immunohistochemistry of paraffin embedded formalin fixed tissues was performed as previously described (Wegiel et al., 2013).
Slides containing either FFPE sections or cells underwent a rehydration procedure, followed by high pressure-cooking antigen
retrieval method in citrate buffer, blocking with 7% horse serum (Vector Laboratories) and overnight incubation with primary anti-
bodies at 4C. After washing with PBS, slides were blocked with H2O2 followed by incubation with either Alexa Fluor conjugated sec-
ondary antibodies (Thermo Scientific) or biotin-labeled secondary antibodies (Vector Laboratories) for 1 h at RT. For immunofluores-
cence, slides were then contrast stained with Hoechst, dried, and mounted with gelvatol. For light microscopy, Vectastain Elite ABC
System was used to enhance the signals (Vector Laboratories) for 30 minutes followed by reaction development with DAB Substrate
(Vector Laboratories).
Nuclear/Cytoplasmic Fractionation
Fractions were isolated using the nuclear/cytoplasmic fractionation kit (BioVision) according tomanufacturer’s protocol. Briefly, cells
were trypsinized, washed once with PBS, and incubated on ice for 10 minutes with cytosolic extraction buffer A after which cytosolic
extraction buffer Bwas added, vortexed, and then placed on ice for 1minute. After centrifugation, the clear supernatant was removedCell Reports 32, 108181, September 22, 2020 e4
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by sonication to ensure nuclear fraction lysis.
Immunoblotting
Proteins were harvested in lysis buffer (25 mM Tris-HCl, 150 mM NaCl, 1% NP-40, 100 mM NaF, 1 Complete Mini Protease Inhibitor
Cocktail Tablet (Roche)). After sonication, lysates were centrifuged at 12,000 x g at 4 for 10 minutes. Protein concentrations were
measured using the BCA Protein Kit (Pierce). 15-35 mg proteins were applied on 4%–12%NuPAGE Bis-Tris SDS polyacrylamide gel
electrophoresis in MES SDS running system (Novex by Life Technologies) followed by transfer to PVDF membrane (Amersham and
Biorad). Following transfer, membranes were blocked in 5% nonfat milk for one hour. The following antibodies were applied rotating
overnight at 4C: P-(Ser780)-Rb (Cell Signaling), Rb (Cell Signaling), HO-1 (Enzo Laboratories), HO-1 rabbit monoclonal (Abcam),
P-(Ser139)-H2AX (gH2AX) (Cell Signaling), cyclin B1 (Santa Cruz Biotechnology), P-(Ser1981)-ATM (Cell Signaling), c-myc (Santa
Cruz Biotechnology), and P-(Ser10)Histone H3 (Cell Signaling). b-Actin (Sigma Aldrich) was used for total lysates while lamin A/C
and GAPDH (Cell Signaling Technologies) were used for nuclear and cytoplasmic loading controls, respectively. The following
day, after brief washing with Tris-buffered saline, membranes were incubated with HRP conjugated secondary antibodies (Cell
Signaling Technologies), followed by chemiluminescent (ECL, Thermo Fisher) detection on film (Bioexpress) or by Chemi Chemi-
Doc Touch Imaging System (Bio-Rad).
Chromatin immunoprecipitation (ChIP):
ChIP was performed as previously described by Zhang et al. (2013). Briefly, treated and untreated PC3 cells were washed twice
with PBS and then crosslinked with 1% formaldehyde. Cell pellets were washed twice with ice-cold 1X PBS (freshly supplemented
with 1 mM PMSF). Pellets of 3 x106 cells were used for immunoprecipitation and lysed for 10 minutes on ice and chromatin frag-
mented using a Bioruptor Model 300, Diagenode (20 cycles, 30 s on, 60 s off, high power). Each ChIP was performed with 1 to 8 mg
of the following antibodies: anti-Nucleolin (Abcam), anti-NM23H2 (Santa Cruz Biotechnology), anti-hnRNPK (Abcam), anti-CNBP
(Santa Cruz Biotechnology), normal mouse IgG (Millipore 12-371b), and then incubated overnight at 4C. A slurry of protein G mag-
netic beads (NEB) was used to capture enriched chromatin, which was then washed before reverse-crosslinking and proteinase K
digestion at 65C. Beads were then removed in the magnetic field and RNase treatment (5mg/ml Epicenter MRNA092) performed for
30 minutes at 37C. ChIP DNA was extracted with Phenol:chloroform:isoamyl Alcohol 25:24:1, pH:8 (Sigma) and then precipitated
with equal volume of isopropanol in presence of glycogen. DNA pellet was dissolved in 30ml of TE buffer for following qPCR
analyses.
ChIP with flagged BG4 antibody (Millipore), was performed in the same conditions of lysis buffer and shering chromatin. 2 to 10 mg
of antibody were initially incubated with the lysate at 4C, O/N and then Anti-FLAGM2Magnetic Beads (Sigma) were used to capture
the fragmeted chromatin as previously described (Zhang et al., 2013). DNA isolated samples were all analyzed by quantitative real
time PCR using the following primers: (c-MYC promoter) F: 50 GCTGGAAACCTTGCACCTC, R: 50 CGTTCAGGTTTGCGAAAGTA.
Fold enrichment was calculated using the formula 2 (-DDCt (ChIP/non-immune serum)).
RNA-sequencing
RNA was isolated from PC3 cells lysed in TRIzol reagent after treatment with heme for 2 or 4 hours. Biological duplicates were pre-
pared. RNA quality was assessed using Bioanlyzer. Libraries were prepared using Illumina Truseq stranded Kit and sequenced on a
BGI-SEQ, PE100 resulting in libraries with 40M reads per sample.
Oligonucleotides, EMSA and Circular Dichroism
Oligonucleotides (Life Technologies) were purified by 15%denaturing polyacrylamide gel electrophoresis followed by elution inwater
and ethanol precipitation overnight. Oligonucleotides were then end labeled with [g-32P] ATP (Perkin Elmer) and T4 polynucleotide
kinase (Roche/Sigma) and then passed through G-25 columns to remove unlabeled oligonucleotides. Labeled oligos were folded in
10 mM Tris-HCl pH 7.4 with or without 100 mM KCl in a PCR machine (BioRad) according to the following protocol: 95C for
5 minutes, followed by slow cooling to 26C over 1.5 hours. Binding reactions with or without IgG or BG4 antibodies were carried
out using the Active Motif GelShift system of binding, stabilizing and dilution buffers (Active Motif) and run on 6% polyacrylamide
gel. The gel was then dried and exposed to X-ray film and/or PhosphorImager screens. Oligonuclotides sequences used are as
follows: Pu27 50TGG GGA GGG TGG GGA GGG TGG GGA AGG 30, Mutated Pu27 50 TGA GTA GCG TGA GCA GAG TGC GTA
ACG 30 (Siddiqui-Jain et al., 2002). Circular dichroism and characterization of the melting temperature of the G4:heme complexes
were performed as previously described (Siddiqui-Jain et al., 2002).
Real time PCR
RNA was isolated from snap-frozen tissues or cells (QIAGEN) according to manufacturer’s protocol and eluted with water. 1 mg of
isolated RNA, measured using Nanodrop, was then used to make cDNA using the iScript Reverse Transcription Supermix (BioRad)
in 20 ml reaction. 1 ml of the undiluted cDNA was then used with SYBR green PCRMaster Mix (Bio-Rad). Primer used were as follows:e5 Cell Reports 32, 108181, September 22, 2020
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ATTTGTCAGAGGCCCTGAAGG; RV: TGTGGTACAGGGAGGCCATCACC; c-MYC human FW: 50ATGAAAAGGCCCCCAAG
GTAGTTATCC; RV: 50GTCGTTTCCGCAACAAGTCCTCTTC; c-MYC, mouse FW: GCCCAGTGAGGATATCTGGA, RV: ATCGCAGAT
GAAGCTCTGGT; MMP2, human FW: CGGCCGCAGTGACGGAAA, RV: CATCCTGGGACAGACGGAAG; MMP2, mouse FW:
GTCGCCCCTAAAACAGACAA, RV: GGTCTCGATGGTGTTCTGGT; MMP9, human FW: TTGACAGCGACAAGAAGTGG, RV:
GCCATTCACGTCGTCCTTAT; MMP9, mouse FW: CGTCGTGATCCCCACTTACT, RV: AACACACAGGGTTTGCCTTC; uPA, human
FW: CAGGGCATCTCCTGTGCATG, RV: AGCCCTGCCCTGAAGTCGTTA; uPA, mouse FW: GCCTGCTGTCCTTCAGAAAC, RV:
TAGAGCCTTCTGGCCACACT; AMIGO2, human FW: TCGTTTGCAAAGCTGAACAC, RV: GCAGAAGCACTTCCAGAACC; AMIGO2,
mouse FW: TCACGGGAACCCATTTGTAT, RV: CTGAGCCTCGTGGATAAAGC; ULK1, human FW: CAGAACTACCAGCGCATTGA,
RV: TCCACCCAGAGACATCTTCC; ULK1, mouse FW: CCCAGAGTACCCGTACCAGA, RV: GTGTAGGGTTTCCGTGTGCT;
ZNF469, human/mouse FW: CGCGAAGACCTTCCTGTTAG, RV: CTCTGTGATGAGGCTGTCCA; ALAS1, FW: TCTTCCGCAAGGC
CAGTCT, RV: TGGGCTTGAGCAGCCTCTT.
Viability assay
Cell viability was measured as previously described (Hedblom et al., 2019). Briefly, 2000 cells were plated in a 96 well plate and
treated with increasing concentrations of GQC-05. After incubation, cells were stained with Crystal Violet solution (Sigma-Aldrich)
for 20 min at room temperature and then extensively washed in double-distilled water. Wells were dried and 10% acetic acid was
added to each well to dissolve the staining. The absorbance was measured at 560 nm using an ELISA plate reader.
Geo Profiles
GEOprofiles from 18 normal prostatic tissues (without any pathological alterations), 62 tissues adjacent to tumors, 64 primary tumors
and 24 metastatic samples were obtained from patients with prostate cancer as described in previously published data (Chandran
et al., 2007; Nemeth et al., 2015). Metastatic biopsies were derived from patients with prostate cancer metastases to the liver, lymph
nodes, kidney, lung and adrenal glands.
Heme and hemopexin measurement
Heme levels were measured using colorimetric kit following manufacturer protocol (Biovision). All experiments were also repeated
using benzidine staining. The o-dianisidine stock solution was prepared (o-dianisidine: 60mg and 0.3 mL glacial acetic acid,
29.7 mL water) and used for staining immediately after mixing with 30% hydrogen peroxide. This working solution was added to
the lysate in a proportion of 1:10. The absorbance of the colorimetric reaction was read by ELISA plate reader at 570 nm. In alternative
method, cells seeded on the glass coverslips were stained with working solution followed by extensive washing and fixation with PFA
and staining of the nuclei with hematoxylin. Hemopexin levels were measured using a colorimetric ELISA kit (Abcam ab108859)
following manufacturer’s protocol.
QUANTIFICATION AND STATISTICAL ANALYSIS
RNA-seq bioinformatics analyses
Raw fastq files first had optical duplicates removed using clumpify from the BBTools suite using the flag ‘‘dedupe spany addcount.’’
Next, adaptor trimming was performed using bbduk, also from the BBTools suite using the flag ‘‘ktrim=l hdist=2.’’ Next, reads were
quality trimmed with Trimmomatic in paired end mode with the flags ‘‘ILLUMINACLIP: <adapter_path> Truseq3.PE.fa:2:15:4:4:true
LEADING:20 TRAILING:20 SLIDINGWINDOW:4:15 MINLEN:25.’’ Alignment was performed using STAR with the flags ‘‘–outFilter-
ScoreMinOverLread 0.1–outFilterMatchNminOverLread 0.1–outFilterMultimapNmax 1’’ with the resultant bam files sorted and in-
dexed using samtools. BamCoverage was used to generate coverage maps using default parameters. HTSeqCount was used to
generate gene counts values using the flags ‘‘–stranded=no–mode=intersection-nonempty.
Differential Gene Expression, Pathway and Gene Set Enrichment Analysis
Differential gene expression analysis was performed following an available tutorial (https://combine-australia.github.io/RNAseq-R/
06-rnaseq-day1.html). Briefly, cpm counts were calculated and genes with cpm values < 0.5 were excluded. Normalization factors
were then calculated for TMM normalization. Differential expression was calculated using limma-voom using appropriate design
matrices. Finally, appropriate contrasts were applied, and differential gene expression tables generated for the appropriate test con-
ditions. Differential gene expression lists were then uploaded to QIAGEN’s Ingenuity Pathway Analysis suite and analyzed online.
Ranked gene lists based on the differential gene expression lists were used for Gene Set Enrichment Analysis using the Broad Insti-




All data are presented as mean ± standard error of the mean (SEM) unless otherwise indicated. Statistical analysis was performed
using one-way or two-way analysis of variance (ANOVA) followed by the post hoc Tukey or Bonferroni test or using unpaired T stu-
dent test using PrismGraphpad and Excel software. Differences between groups were rated significant at values of p < 0.05. Kaplan-
Meier survival curve analysis was performed in SPSS (IBM, USA). Median value was used to dichotomize the data into ‘‘low’’ and
‘‘high.’’ Cox regression was used to determine hazard ratios, confidence intervals and p value. Details on the statistical method
used are reported in each figure legend.e7 Cell Reports 32, 108181, September 22, 2020
